_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,direction,b1,b2,direction_gold,e1,e2,relation,relex_relcos,sent_id,sentence,term1,term2,twrex
502813464,7/13/2014 15:38:12,,1321944224,7/13/2014 15:37:48,clixsense,0.7361,27871219,NLD,07,Amsterdam,87.210.207.223,no_relation,124,9,,146,35,causes,0.538815906080325,905078-FS1-4,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,RO-has_finding_site
502813464,7/13/2014 15:58:14,,1321951810,7/13/2014 15:58:02,clixsense,0.6639,27793793,GBR,C5,Chester,151.230.27.155,no_relation,124,9,,146,35,causes,0.538815906080325,905078-FS1-4,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,RO-has_finding_site
502813464,7/13/2014 16:00:23,,1321952621,7/13/2014 15:59:48,clixsense,0.6083,25402344,CAN,ON,Wawa,24.109.124.45,INFLAMMATORY BOWEL DISEASE causes GASTROINTESTINAL TRACT,124,9,,146,35,causes,0.538815906080325,905078-FS1-4,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,RO-has_finding_site
502813464,7/13/2014 16:14:50,,1321958276,7/13/2014 16:14:30,neodev,0.6407,14861092,GBR,I2,Manchester,90.194.137.76,no_relation,124,9,,146,35,causes,0.538815906080325,905078-FS1-4,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,RO-has_finding_site
502813464,7/13/2014 16:25:38,,1321962174,7/13/2014 16:25:13,prodege,0.675,19192508,USA,OK,Broken Arrow,70.177.111.89,no_relation,124,9,,146,35,causes,0.538815906080325,905078-FS1-4,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,RO-has_finding_site
502813464,7/13/2014 16:27:52,,1321963205,7/13/2014 16:27:05,elite,0.304,28276268,USA,CA,San Diego,76.88.95.100,INFLAMMATORY BOWEL DISEASE causes GASTROINTESTINAL TRACT,124,9,,146,35,causes,0.538815906080325,905078-FS1-4,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,RO-has_finding_site
502813464,7/13/2014 16:45:55,,1321970225,7/13/2014 16:45:33,instagc,0.5933,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,124,9,,146,35,causes,0.538815906080325,905078-FS1-4,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,RO-has_finding_site
502813465,7/13/2014 15:42:29,,1321945838,7/13/2014 15:42:21,neodev,0.6488,17610000,GBR,I2,Manchester,90.200.140.201,PHARMACOLOGIC MYDRIASIS diagnosed by TOPICAL PILOCARPINE,75,118,,98,137,diagnosed by,0.845154254728516,908182-FS1-13,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE,RO-may_treat
502813465,7/13/2014 15:45:42,,1321946986,7/13/2014 15:45:10,prodege,0.6736,27096445,GBR,H9,London,86.186.168.254,PHARMACOLOGIC MYDRIASIS diagnosed by TOPICAL PILOCARPINE,75,118,,98,137,diagnosed by,0.845154254728516,908182-FS1-13,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE,RO-may_treat
502813465,7/13/2014 15:52:39,,1321949560,7/13/2014 15:52:05,uniquerewards,0.6917,20281752,GBR,M1,Slough,86.136.105.36,PHARMACOLOGIC MYDRIASIS diagnosed by TOPICAL PILOCARPINE,75,118,,98,137,diagnosed by,0.845154254728516,908182-FS1-13,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE,RO-may_treat
502813465,7/13/2014 16:14:09,,1321957960,7/13/2014 16:13:46,neodev,0.6407,14861092,GBR,I2,Manchester,90.194.137.76,TOPICAL PILOCARPINE diagnosed by PHARMACOLOGIC MYDRIASIS,75,118,,98,137,diagnosed by,0.845154254728516,908182-FS1-13,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE,RO-may_treat
502813465,7/13/2014 16:21:13,,1321960484,7/13/2014 16:20:32,prodege,0.6149,28039757,GBR,L8,Southport,109.155.158.54,PHARMACOLOGIC MYDRIASIS diagnosed by TOPICAL PILOCARPINE,75,118,,98,137,diagnosed by,0.845154254728516,908182-FS1-13,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE,RO-may_treat
502813465,7/13/2014 16:27:52,,1321963203,7/13/2014 16:27:05,elite,0.304,28276268,USA,CA,San Diego,76.88.95.100,PHARMACOLOGIC MYDRIASIS diagnosed by TOPICAL PILOCARPINE,75,118,,98,137,diagnosed by,0.845154254728516,908182-FS1-13,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE,RO-may_treat
502813465,7/13/2014 16:34:57,,1321966252,7/13/2014 16:34:41,instagc,0.4853,25990856,USA,NV,Las Vegas,68.108.98.78,no_relation,75,118,,98,137,diagnosed by,0.845154254728516,908182-FS1-13,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE,RO-may_treat
502813466,7/13/2014 15:53:05,,1321949697,7/13/2014 15:52:40,uniquerewards,0.6917,20281752,GBR,M1,Slough,86.136.105.36,MYOCLONIC SEIZURE causes KINDLED SEIZURES,67,128,,83,145,causes,0.845154254728516,904708-FS1-4,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE,RO-has_definitional_manifestation
502813466,7/13/2014 16:20:31,,1321960262,7/13/2014 16:19:52,prodege,0.6149,28039757,GBR,L8,Southport,109.155.158.54,MYOCLONIC SEIZURE causes KINDLED SEIZURES,67,128,,83,145,causes,0.845154254728516,904708-FS1-4,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE,RO-has_definitional_manifestation
502813466,7/13/2014 16:21:21,,1321960508,7/13/2014 16:20:34,rewardsspot,0.5812,24482174,GBR,H9,London,46.23.68.180,MYOCLONIC SEIZURE causes KINDLED SEIZURES,67,128,,83,145,causes,0.845154254728516,904708-FS1-4,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE,RO-has_definitional_manifestation
502813466,7/13/2014 16:26:08,,1321962389,7/13/2014 16:25:40,prodege,0.675,19192508,USA,OK,Broken Arrow,70.177.111.89,MYOCLONIC SEIZURE causes KINDLED SEIZURES,67,128,,83,145,causes,0.845154254728516,904708-FS1-4,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE,RO-has_definitional_manifestation
502813466,7/13/2014 16:30:20,,1321964393,7/13/2014 16:29:51,elite,0.304,28276268,USA,CA,San Diego,76.88.95.100,KINDLED SEIZURES causes MYOCLONIC SEIZURE,67,128,,83,145,causes,0.845154254728516,904708-FS1-4,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE,RO-has_definitional_manifestation
502813466,7/13/2014 16:38:55,,1321967877,7/13/2014 16:38:38,instagc,0.5571,20183814,USA,"","",166.182.83.213,MYOCLONIC SEIZURE causes KINDLED SEIZURES,67,128,,83,145,causes,0.845154254728516,904708-FS1-4,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE,RO-has_definitional_manifestation
502813466,7/13/2014 16:45:31,,1321970058,7/13/2014 16:44:49,instagc,0.5933,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,67,128,,83,145,causes,0.845154254728516,904708-FS1-4,These results suggest that the CSH induced long term inhibition of KINDLED SEIZURES is the result of an interaction between the MYOCLONIC SEIZURE and a subsequent kindled seizure.,KINDLED SEIZURES,MYOCLONIC SEIZURE,RO-has_definitional_manifestation
502813467,7/13/2014 15:41:32,,1321945519,7/13/2014 15:41:10,instagc,0.7889,28301350,GBR,K4,Plymouth,89.241.102.134,OVARIES is location of OVARIAN ADENOCARCINOMA,212,153,,219,175,is location of,0.944911182523068,902097-FS1-9,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA,RO-disease_has_primary_anatomic_site
502813467,7/13/2014 16:21:13,,1321960489,7/13/2014 16:20:32,prodege,0.6149,28039757,GBR,L8,Southport,109.155.158.54,no_relation,212,153,,219,175,is location of,0.944911182523068,902097-FS1-9,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA,RO-disease_has_primary_anatomic_site
502813467,7/13/2014 16:46:45,,1321970562,7/13/2014 16:45:57,instagc,0.5933,24252915,GBR,B7,Bristol,77.98.139.82,OVARIES is location of OVARIAN ADENOCARCINOMA,212,153,,219,175,is location of,0.944911182523068,902097-FS1-9,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA,RO-disease_has_primary_anatomic_site
502813467,7/13/2014 16:48:40,,1321971335,7/13/2014 16:48:11,neodev,0.7345,27597779,CAN,AB,Calgary,68.146.86.137,OVARIES is location of OVARIAN ADENOCARCINOMA,212,153,,219,175,is location of,0.944911182523068,902097-FS1-9,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA,RO-disease_has_primary_anatomic_site
502813467,7/13/2014 17:01:03,,1321975529,7/13/2014 17:00:26,clixsense,0.5437,28037714,GBR,I4,Mitcham,94.4.232.118,OVARIES is location of OVARIAN ADENOCARCINOMA,212,153,,219,175,is location of,0.944911182523068,902097-FS1-9,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA,RO-disease_has_primary_anatomic_site
502813467,7/13/2014 17:05:41,,1321976962,7/13/2014 17:05:18,clixsense,0.5,21917173,CAN,"","",24.71.41.51,no_relation,212,153,,219,175,is location of,0.944911182523068,902097-FS1-9,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA,RO-disease_has_primary_anatomic_site
502813467,7/13/2014 17:09:56,,1321978452,7/13/2014 17:09:22,prodege,0.4286,2422962,USA,IA,Honey Creek,12.73.110.97,no_relation,212,153,,219,175,is location of,0.944911182523068,902097-FS1-9,"The autologous membrane bound antibodies strongly recognized cell surface antigens on four human ovarian cell lines and four surgical specimens of human OVARIAN ADENOCARCINOMA but did not react with normal human OVARIES non ovarian normal and neoplastic tissues, or non ovarian human cell lines by indirect immunofluorescence assay.",OVARIES,OVARIAN ADENOCARCINOMA,RO-disease_has_primary_anatomic_site
502813468,7/13/2014 15:41:57,,1321945673,7/13/2014 15:41:44,neodev,0.6488,17610000,GBR,I2,Manchester,90.200.140.201,SKIN is location of PERSPIRATION,439,419,,443,431,is location of,0.980196058819607,905376-FS1-9,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION,RO-has_finding_site
502813468,7/13/2014 15:58:01,,1321951690,7/13/2014 15:57:48,clixsense,0.6639,27793793,GBR,C5,Chester,151.230.27.155,SKIN is location of PERSPIRATION,439,419,,443,431,is location of,0.980196058819607,905376-FS1-9,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION,RO-has_finding_site
502813468,7/13/2014 16:12:06,,1321957137,7/13/2014 16:11:50,fusioncash,0.6208,22139728,USA,"","",66.67.91.242,SKIN is location of PERSPIRATION,439,419,,443,431,is location of,0.980196058819607,905376-FS1-9,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION,RO-has_finding_site
502813468,7/13/2014 16:19:28,,1321959985,7/13/2014 16:18:29,clixsense,0.2,25595227,CAN,SK,North Battleford,24.72.96.119,PERSPIRATION is location of SKIN,439,419,,443,431,is location of,0.980196058819607,905376-FS1-9,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION,RO-has_finding_site
502813468,7/13/2014 16:25:12,,1321962008,7/13/2014 16:24:42,prodege,0.675,19192508,USA,OK,Broken Arrow,70.177.111.89,SKIN is location of PERSPIRATION,439,419,,443,431,is location of,0.980196058819607,905376-FS1-9,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION,RO-has_finding_site
502813468,7/13/2014 16:44:48,,1321969821,7/13/2014 16:44:24,instagc,0.5933,24252915,GBR,B7,Bristol,77.98.139.82,SKIN is location of PERSPIRATION,439,419,,443,431,is location of,0.980196058819607,905376-FS1-9,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION,RO-has_finding_site
502813468,7/13/2014 16:48:10,,1321971148,7/13/2014 16:47:46,neodev,0.7345,27597779,CAN,AB,Calgary,68.146.86.137,SKIN is location of PERSPIRATION,439,419,,443,431,is location of,0.980196058819607,905376-FS1-9,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in PERSPIRATION on the SKIN",SKIN,PERSPIRATION,RO-has_finding_site
502813469,7/13/2014 15:36:13,,1321943426,7/13/2014 15:36:05,neodev,0.7292,28336203,USA,PA,Harrisburg,50.149.53.150,SMALL JOINTS OF THE HANDS is location of ARTHRITIS,178,227,,203,236,is location of,0.872871560943969,902259-FS1-9,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS,RO-disease_has_primary_anatomic_site
502813469,7/13/2014 15:37:09,,1321943827,7/13/2014 15:37:02,neodev,0.5278,25224036,CAN,ON,Sudbury,67.204.218.187,ARTHRITIS is location of SMALL JOINTS OF THE HANDS,178,227,,203,236,is location of,0.872871560943969,902259-FS1-9,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS,RO-disease_has_primary_anatomic_site
502813469,7/13/2014 15:39:36,,1321944730,7/13/2014 15:39:20,instagc,0.7889,28301350,GBR,K4,Plymouth,89.241.102.134,SMALL JOINTS OF THE HANDS is location of ARTHRITIS,178,227,,203,236,is location of,0.872871560943969,902259-FS1-9,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS,RO-disease_has_primary_anatomic_site
502813469,7/13/2014 15:42:20,,1321945806,7/13/2014 15:42:14,neodev,0.6488,17610000,GBR,I2,Manchester,90.200.140.201,SMALL JOINTS OF THE HANDS is location of ARTHRITIS,178,227,,203,236,is location of,0.872871560943969,902259-FS1-9,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS,RO-disease_has_primary_anatomic_site
502813469,7/13/2014 15:43:55,,1321946395,7/13/2014 15:43:12,prodege,0.6736,27096445,GBR,H9,London,86.186.168.254,SMALL JOINTS OF THE HANDS is location of ARTHRITIS,178,227,,203,236,is location of,0.872871560943969,902259-FS1-9,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS,RO-disease_has_primary_anatomic_site
502813469,7/13/2014 15:52:04,,1321949339,7/13/2014 15:51:25,uniquerewards,0.6917,20281752,GBR,M1,Slough,86.136.105.36,SMALL JOINTS OF THE HANDS is location of ARTHRITIS,178,227,,203,236,is location of,0.872871560943969,902259-FS1-9,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS,RO-disease_has_primary_anatomic_site
502813469,7/13/2014 15:57:45,,1321951579,7/13/2014 15:57:32,clixsense,0.6639,27793793,GBR,C5,Chester,151.230.27.155,no_relation,178,227,,203,236,is location of,0.872871560943969,902259-FS1-9,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the SMALL JOINTS OF THE HANDS in three, shoulder periARTHRITIS in two and costal cartilage pain in one.",SMALL JOINTS OF THE HANDS,ARTHRITIS,RO-disease_has_primary_anatomic_site
502813470,7/13/2014 15:34:36,,1321942723,7/13/2014 15:34:29,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,HAEMATURIA causes RENAL CELL CARCINOMA,72,50,,82,70,causes,0.927172649945531,902711-FS1-4,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA,RO-disease_may_have_finding
502813470,7/13/2014 15:37:47,,1321944045,7/13/2014 15:37:10,clixsense,0.7361,27871219,NLD,07,Amsterdam,87.210.207.223,RENAL CELL CARCINOMA causes HAEMATURIA,72,50,,82,70,causes,0.927172649945531,902711-FS1-4,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA,RO-disease_may_have_finding
502813470,7/13/2014 15:58:28,,1321951878,7/13/2014 15:58:16,clixsense,0.6639,27793793,GBR,C5,Chester,151.230.27.155,RENAL CELL CARCINOMA causes HAEMATURIA,72,50,,82,70,causes,0.927172649945531,902711-FS1-4,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA,RO-disease_may_have_finding
502813470,7/13/2014 16:11:02,,1321956654,7/13/2014 16:10:58,bitcoinget,0.4236,27786287,USA,FL,Jacksonville,76.106.186.209,no_relation,72,50,,82,70,causes,0.927172649945531,902711-FS1-4,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA,RO-disease_may_have_finding
502813470,7/13/2014 16:14:29,,1321958139,7/13/2014 16:14:10,neodev,0.6407,14861092,GBR,I2,Manchester,90.194.137.76,no_relation,72,50,,82,70,causes,0.927172649945531,902711-FS1-4,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA,RO-disease_may_have_finding
502813470,7/13/2014 16:26:08,,1321962398,7/13/2014 16:25:40,prodege,0.675,19192508,USA,OK,Broken Arrow,70.177.111.89,RENAL CELL CARCINOMA causes HAEMATURIA,72,50,,82,70,causes,0.927172649945531,902711-FS1-4,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA,RO-disease_may_have_finding
502813470,7/13/2014 16:39:39,,1321968141,7/13/2014 16:39:21,instagc,0.5571,20183814,USA,"","",166.182.83.213,RENAL CELL CARCINOMA causes HAEMATURIA,72,50,,82,70,causes,0.927172649945531,902711-FS1-4,The major symptoms are the same as in the classic RENAL CELL CARCINOMA: HAEMATURIA and flank pain.,HAEMATURIA,RENAL CELL CARCINOMA,RO-disease_may_have_finding
502813471,7/13/2014 15:38:12,,1321944225,7/13/2014 15:37:48,clixsense,0.7361,27871219,NLD,07,Amsterdam,87.210.207.223,20 WEEK BINGE PROGRAMME treats BINGE EATING,219,170,,231,193,treats,0.848528137423857,904800-FS1-2,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME,RO-has_definitional_manifestation
502813471,7/13/2014 15:38:21,,1321944263,7/13/2014 15:38:07,instagc,0.7153,18960682,GBR,"","",86.29.147.112,20 WEEK BINGE PROGRAMME treats BINGE EATING,219,170,,231,193,treats,0.848528137423857,904800-FS1-2,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME,RO-has_definitional_manifestation
502813471,7/13/2014 15:39:36,,1321944731,7/13/2014 15:39:20,instagc,0.7889,28301350,GBR,K4,Plymouth,89.241.102.134,20 WEEK BINGE PROGRAMME treats BINGE EATING,219,170,,231,193,treats,0.848528137423857,904800-FS1-2,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME,RO-has_definitional_manifestation
502813471,7/13/2014 15:58:28,,1321951886,7/13/2014 15:58:16,clixsense,0.6639,27793793,GBR,C5,Chester,151.230.27.155,20 WEEK BINGE PROGRAMME treats BINGE EATING,219,170,,231,193,treats,0.848528137423857,904800-FS1-2,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME,RO-has_definitional_manifestation
502813471,7/13/2014 16:12:21,,1321957229,7/13/2014 16:12:07,fusioncash,0.6208,22139728,USA,"","",66.67.91.242,20 WEEK BINGE PROGRAMME treats BINGE EATING,219,170,,231,193,treats,0.848528137423857,904800-FS1-2,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME,RO-has_definitional_manifestation
502813471,7/13/2014 16:22:55,,1321961054,7/13/2014 16:22:16,prodege,0.6149,28039757,GBR,L8,Southport,109.155.158.54,20 WEEK BINGE PROGRAMME treats BINGE EATING,219,170,,231,193,treats,0.848528137423857,904800-FS1-2,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME,RO-has_definitional_manifestation
502813471,7/13/2014 16:39:20,,1321968059,7/13/2014 16:38:55,instagc,0.5571,20183814,USA,"","",166.182.83.213,20 WEEK BINGE PROGRAMME treats BINGE EATING,219,170,,231,193,treats,0.848528137423857,904800-FS1-2,"The patients were enrolled into three different programmes: a 14 week LEARN programme (672 patients), a 16 week MOB programme for the morbidly obese (259 patients), or a 20 WEEK BINGE PROGRAMME for subjects affected by BINGE EATING (137 patients.",BINGE EATING,20 WEEK BINGE PROGRAMME,RO-has_definitional_manifestation
502813472,7/13/2014 15:39:13,,1321944601,7/13/2014 15:38:59,instagc,0.7153,18960682,GBR,"","",86.29.147.112,BONE is location of OSTEOMYELITIS,181,143,,185,156,is location of,0.993883734673619,902077-FS1-9,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS,RO-disease_has_primary_anatomic_site
502813472,7/13/2014 15:39:52,,1321944831,7/13/2014 15:39:37,instagc,0.7889,28301350,GBR,K4,Plymouth,89.241.102.134,BONE is location of OSTEOMYELITIS,181,143,,185,156,is location of,0.993883734673619,902077-FS1-9,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS,RO-disease_has_primary_anatomic_site
502813472,7/13/2014 16:11:50,,1321956944,7/13/2014 16:11:19,fusioncash,0.6208,22139728,USA,"","",66.67.91.242,OSTEOMYELITIS is location of BONE,181,143,,185,156,is location of,0.993883734673619,902077-FS1-9,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS,RO-disease_has_primary_anatomic_site
502813472,7/13/2014 16:15:52,,1321958723,7/13/2014 16:15:15,neodev,0.6407,14861092,GBR,I2,Manchester,90.194.137.76,BONE is location of OSTEOMYELITIS,181,143,,185,156,is location of,0.993883734673619,902077-FS1-9,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS,RO-disease_has_primary_anatomic_site
502813472,7/13/2014 16:22:55,,1321961055,7/13/2014 16:22:16,prodege,0.6149,28039757,GBR,L8,Southport,109.155.158.54,OSTEOMYELITIS is location of BONE,181,143,,185,156,is location of,0.993883734673619,902077-FS1-9,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS,RO-disease_has_primary_anatomic_site
502813472,7/13/2014 16:24:04,,1321961535,7/13/2014 16:23:37,prodege,0.675,19192508,USA,OK,Broken Arrow,70.177.111.89,BONE is location of OSTEOMYELITIS,181,143,,185,156,is location of,0.993883734673619,902077-FS1-9,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS,RO-disease_has_primary_anatomic_site
502813472,7/13/2014 16:35:19,,1321966405,7/13/2014 16:34:58,instagc,0.4853,25990856,USA,NV,Las Vegas,68.108.98.78,BONE is location of OSTEOMYELITIS,181,143,,185,156,is location of,0.993883734673619,902077-FS1-9,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of OSTEOMYELITIS an infection located in BONE and notoriously difficult to successfully manage.",BONE,OSTEOMYELITIS,RO-disease_has_primary_anatomic_site
502813473,7/13/2014 15:34:27,,1321942702,7/13/2014 15:34:17,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,JOINT is location of JOINT EFFUSION,26,26,,31,40,is location of,0.794719414239026,905403-FS1-9,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION,RO-has_finding_site
502813473,7/13/2014 15:36:39,,1321943616,7/13/2014 15:36:33,neodev,0.5278,25224036,CAN,ON,Sudbury,67.204.218.187,JOINT is location of JOINT EFFUSION,26,26,,31,40,is location of,0.794719414239026,905403-FS1-9,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION,RO-has_finding_site
502813473,7/13/2014 15:37:35,,1321943985,7/13/2014 15:37:17,neodev,0.7292,28336203,USA,PA,Harrisburg,50.149.53.150,JOINT is location of JOINT EFFUSION,26,26,,31,40,is location of,0.794719414239026,905403-FS1-9,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION,RO-has_finding_site
502813473,7/13/2014 15:38:57,,1321944513,7/13/2014 15:38:42,instagc,0.7153,18960682,GBR,"","",86.29.147.112,JOINT is location of JOINT EFFUSION,26,26,,31,40,is location of,0.794719414239026,905403-FS1-9,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION,RO-has_finding_site
502813473,7/13/2014 15:45:09,,1321946810,7/13/2014 15:44:37,prodege,0.6736,27096445,GBR,H9,London,86.186.168.254,JOINT is location of JOINT EFFUSION,26,26,,31,40,is location of,0.794719414239026,905403-FS1-9,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION,RO-has_finding_site
502813473,7/13/2014 16:11:50,,1321956949,7/13/2014 16:11:19,fusioncash,0.6208,22139728,USA,"","",66.67.91.242,JOINT is location of JOINT EFFUSION,26,26,,31,40,is location of,0.794719414239026,905403-FS1-9,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION,RO-has_finding_site
502813473,7/13/2014 16:30:45,,1321964542,7/13/2014 16:30:23,elite,0.304,28276268,USA,CA,San Diego,76.88.95.100,JOINT EFFUSION is location of JOINT,26,26,,31,40,is location of,0.794719414239026,905403-FS1-9,It has been reported that JOINT EFFUSION the excessive accumulation of joint fluid in and around the JOINT is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.,JOINT,JOINT EFFUSION,RO-has_finding_site
502813474,7/13/2014 15:35:31,,1321943086,7/13/2014 15:35:17,clixsense,0.9167,15189335,GBR,K3,Peterborough,81.156.166.189,MIGRAINE causes HEADACHE,254,166,,262,174,causes,0.74535599249993,904663-FS1-4,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE,RO-has_definitional_manifestation
502813474,7/13/2014 15:36:13,,1321943427,7/13/2014 15:36:05,neodev,0.7292,28336203,USA,PA,Harrisburg,50.149.53.150,MIGRAINE causes HEADACHE,254,166,,262,174,causes,0.74535599249993,904663-FS1-4,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE,RO-has_definitional_manifestation
502813474,7/13/2014 15:38:21,,1321944262,7/13/2014 15:38:07,instagc,0.7153,18960682,GBR,"","",86.29.147.112,no_relation,254,166,,262,174,causes,0.74535599249993,904663-FS1-4,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE,RO-has_definitional_manifestation
502813474,7/13/2014 15:38:46,,1321944434,7/13/2014 15:38:14,clixsense,0.7361,27871219,NLD,07,Amsterdam,87.210.207.223,MIGRAINE causes HEADACHE,254,166,,262,174,causes,0.74535599249993,904663-FS1-4,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE,RO-has_definitional_manifestation
502813474,7/13/2014 15:40:30,,1321945076,7/13/2014 15:39:53,instagc,0.7889,28301350,GBR,K4,Plymouth,89.241.102.134,MIGRAINE causes HEADACHE,254,166,,262,174,causes,0.74535599249993,904663-FS1-4,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE,RO-has_definitional_manifestation
502813474,7/13/2014 15:42:04,,1321945706,7/13/2014 15:41:59,neodev,0.6488,17610000,GBR,I2,Manchester,90.200.140.201,HEADACHE causes MIGRAINE,254,166,,262,174,causes,0.74535599249993,904663-FS1-4,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE,RO-has_definitional_manifestation
502813474,7/13/2014 16:10:58,,1321956642,7/13/2014 16:10:43,bitcoinget,0.4236,27786287,USA,FL,Jacksonville,76.106.186.209,no_relation,254,166,,262,174,causes,0.74535599249993,904663-FS1-4,"Gamma aminobutyric acid levels in saliva were 36.8 +/  49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/  25.2 pmol/mL in the patients with MIGRAINE in interictal periods, 16.0 +/  18.3 pmol/mL in the patients with tension type HEADACHE during active headache periods, 14.1 +/  6.8 pmol/mL in the patients with tension type headache in headache free periods, and 21.6 +/  22.7 pmol/mL in the healthy controls.",HEADACHE,MIGRAINE,RO-has_definitional_manifestation
502813475,7/13/2014 15:36:23,,1321943504,7/13/2014 15:35:56,clixsense,0.7361,27871219,NLD,07,Amsterdam,87.210.207.223,HANTAVIRUS causes HANTAVIRUS PULMONARY SYNDROME,0,0,,10,29,causes,0.943879807448539,903801-FS1-4,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME,RO-has_causative_agent
502813475,7/13/2014 15:37:01,,1321943730,7/13/2014 15:36:54,neodev,0.5278,25224036,CAN,ON,Sudbury,67.204.218.187,HANTAVIRUS PULMONARY SYNDROME causes HANTAVIRUS,0,0,,10,29,causes,0.943879807448539,903801-FS1-4,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME,RO-has_causative_agent
502813475,7/13/2014 15:39:51,,1321944842,7/13/2014 15:39:33,instagc,0.7153,18960682,GBR,"","",86.29.147.112,HANTAVIRUS causes HANTAVIRUS PULMONARY SYNDROME,0,0,,10,29,causes,0.943879807448539,903801-FS1-4,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME,RO-has_causative_agent
502813475,7/13/2014 16:10:23,,1321956460,7/13/2014 16:10:03,bitcoinget,0.4236,27786287,USA,FL,Jacksonville,76.106.186.209,HANTAVIRUS causes HANTAVIRUS PULMONARY SYNDROME,0,0,,10,29,causes,0.943879807448539,903801-FS1-4,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME,RO-has_causative_agent
502813475,7/13/2014 16:21:21,,1321960507,7/13/2014 16:20:34,rewardsspot,0.5812,24482174,GBR,H9,London,46.23.68.180,HANTAVIRUS PULMONARY SYNDROME causes HANTAVIRUS,0,0,,10,29,causes,0.943879807448539,903801-FS1-4,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME,RO-has_causative_agent
502813475,7/13/2014 16:23:31,,1321961256,7/13/2014 16:22:57,prodege,0.6149,28039757,GBR,L8,Southport,109.155.158.54,HANTAVIRUS causes HANTAVIRUS PULMONARY SYNDROME,0,0,,10,29,causes,0.943879807448539,903801-FS1-4,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME,RO-has_causative_agent
502813475,7/13/2014 16:36:09,,1321966812,7/13/2014 16:35:56,instagc,0.4853,25990856,USA,NV,Las Vegas,68.108.98.78,no_relation,0,0,,10,29,causes,0.943879807448539,903801-FS1-4,HANTAVIRUS PULMONARY SYNDROME (HPS) is a viral infection from a new strain of HANTAVIRUS,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME,RO-has_causative_agent
502813476,7/13/2014 15:43:55,,1321946403,7/13/2014 15:43:12,prodege,0.6736,27096445,GBR,H9,London,86.186.168.254,no_relation,489,242,,497,258,treats,0.35921060405355,903790-FS1-2,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS,RO-has_causative_agent
502813476,7/13/2014 15:53:05,,1321949702,7/13/2014 15:52:40,uniquerewards,0.6917,20281752,GBR,M1,Slough,86.136.105.36,FLUORIDE treats DENTAL FLUOROSIS,489,242,,497,258,treats,0.35921060405355,903790-FS1-2,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS,RO-has_causative_agent
502813476,7/13/2014 16:10:01,,1321956283,7/13/2014 16:09:01,bitcoinget,0.4236,27786287,USA,FL,Jacksonville,76.106.186.209,DENTAL FLUOROSIS treats FLUORIDE,489,242,,497,258,treats,0.35921060405355,903790-FS1-2,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS,RO-has_causative_agent
502813476,7/13/2014 16:10:38,,1321956548,7/13/2014 16:09:44,fusioncash,0.6208,22139728,USA,"","",66.67.91.242,FLUORIDE treats DENTAL FLUOROSIS,489,242,,497,258,treats,0.35921060405355,903790-FS1-2,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS,RO-has_causative_agent
502813476,7/13/2014 16:25:29,,1321962127,7/13/2014 16:24:55,rewardsspot,0.5812,24482174,GBR,H9,London,46.23.68.180,FLUORIDE treats DENTAL FLUOROSIS,489,242,,497,258,treats,0.35921060405355,903790-FS1-2,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS,RO-has_causative_agent
502813476,7/13/2014 16:35:55,,1321966712,7/13/2014 16:35:36,instagc,0.4853,25990856,USA,NV,Las Vegas,68.108.98.78,no_relation,489,242,,497,258,treats,0.35921060405355,903790-FS1-2,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS,RO-has_causative_agent
502813476,7/13/2014 16:38:55,,1321967878,7/13/2014 16:38:38,instagc,0.5571,20183814,USA,"","",166.182.83.213,FLUORIDE treats DENTAL FLUOROSIS,489,242,,497,258,treats,0.35921060405355,903790-FS1-2,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS,RO-has_causative_agent
502813477,7/13/2014 15:34:27,,1321942701,7/13/2014 15:34:17,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,PV causes GASTROINTESTINAL BLEEDING,59,102,,84,104,causes,0.617213399848368,902816-FS1-4,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV,RO-disease_may_have_finding
502813477,7/13/2014 15:39:52,,1321944837,7/13/2014 15:39:37,instagc,0.7889,28301350,GBR,K4,Plymouth,89.241.102.134,PV causes GASTROINTESTINAL BLEEDING,59,102,,84,104,causes,0.617213399848368,902816-FS1-4,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV,RO-disease_may_have_finding
502813477,7/13/2014 15:39:51,,1321944843,7/13/2014 15:39:33,instagc,0.7153,18960682,GBR,"","",86.29.147.112,PV causes GASTROINTESTINAL BLEEDING,59,102,,84,104,causes,0.617213399848368,902816-FS1-4,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV,RO-disease_may_have_finding
502813477,7/13/2014 15:44:36,,1321946655,7/13/2014 15:43:56,prodege,0.6736,27096445,GBR,H9,London,86.186.168.254,no_relation,59,102,,84,104,causes,0.617213399848368,902816-FS1-4,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV,RO-disease_may_have_finding
502813477,7/13/2014 16:02:20,,1321953350,7/13/2014 16:02:03,clixsense,0.6083,25402344,CAN,ON,Wawa,24.109.124.45,PV causes GASTROINTESTINAL BLEEDING,59,102,,84,104,causes,0.617213399848368,902816-FS1-4,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV,RO-disease_may_have_finding
502813477,7/13/2014 16:10:42,,1321956573,7/13/2014 16:10:24,bitcoinget,0.4236,27786287,USA,FL,Jacksonville,76.106.186.209,no_relation,59,102,,84,104,causes,0.617213399848368,902816-FS1-4,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV,RO-disease_may_have_finding
502813477,7/13/2014 16:14:29,,1321958138,7/13/2014 16:14:10,neodev,0.6407,14861092,GBR,I2,Manchester,90.194.137.76,PV causes GASTROINTESTINAL BLEEDING,59,102,,84,104,causes,0.617213399848368,902816-FS1-4,? High dose aspirin use has been associated with increased GASTROINTESTINAL BLEEDING in patients with PV,GASTROINTESTINAL BLEEDING,PV,RO-disease_may_have_finding
502813478,7/13/2014 15:51:24,,1321949072,7/13/2014 15:50:54,uniquerewards,0.6917,20281752,GBR,M1,Slough,86.136.105.36,no_relation,75,118,,98,137,treats,0.50709255283711,908182-FS1-2,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE,RO-may_treat
502813478,7/13/2014 15:58:14,,1321951807,7/13/2014 15:58:02,clixsense,0.6639,27793793,GBR,C5,Chester,151.230.27.155,TOPICAL PILOCARPINE treats PHARMACOLOGIC MYDRIASIS,75,118,,98,137,treats,0.50709255283711,908182-FS1-2,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE,RO-may_treat
502813478,7/13/2014 16:15:14,,1321958486,7/13/2014 16:14:51,neodev,0.6407,14861092,GBR,I2,Manchester,90.194.137.76,no_relation,75,118,,98,137,treats,0.50709255283711,908182-FS1-2,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE,RO-may_treat
502813478,7/13/2014 16:23:37,,1321961310,7/13/2014 16:23:11,prodege,0.675,19192508,USA,OK,Broken Arrow,70.177.111.89,no_relation,75,118,,98,137,treats,0.50709255283711,908182-FS1-2,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE,RO-may_treat
502813478,7/13/2014 16:31:06,,1321964727,7/13/2014 16:30:47,elite,0.304,28276268,USA,CA,San Diego,76.88.95.100,PHARMACOLOGIC MYDRIASIS treats TOPICAL PILOCARPINE,75,118,,98,137,treats,0.50709255283711,908182-FS1-2,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE,RO-may_treat
502813478,7/13/2014 16:38:38,,1321967783,7/13/2014 16:38:16,instagc,0.5571,20183814,USA,"","",166.182.83.213,TOPICAL PILOCARPINE treats PHARMACOLOGIC MYDRIASIS,75,118,,98,137,treats,0.50709255283711,908182-FS1-2,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE,RO-may_treat
502813478,7/13/2014 16:44:23,,1321969625,7/13/2014 16:44:00,instagc,0.5933,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,75,118,,98,137,treats,0.50709255283711,908182-FS1-2,"In patients with internal ophthalmoplegia, awareness of the possibility of PHARMACOLOGIC MYDRIASIS and correct use of TOPICAL PILOCARPINE testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",PHARMACOLOGIC MYDRIASIS,TOPICAL PILOCARPINE,RO-may_treat
502813479,7/13/2014 15:35:55,,1321943259,7/13/2014 15:35:25,clixsense,0.7361,27871219,NLD,07,Amsterdam,87.210.207.223,ANGINA causes PAIN,168,143,,172,149,causes,0.896258159530272,904945-FS1-4,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA,RO-has_definitional_manifestation
502813479,7/13/2014 15:37:35,,1321943986,7/13/2014 15:37:17,neodev,0.7292,28336203,USA,PA,Harrisburg,50.149.53.150,PAIN causes ANGINA,168,143,,172,149,causes,0.896258159530272,904945-FS1-4,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA,RO-has_definitional_manifestation
502813479,7/13/2014 15:42:04,,1321945705,7/13/2014 15:41:59,neodev,0.6488,17610000,GBR,I2,Manchester,90.200.140.201,PAIN causes ANGINA,168,143,,172,149,causes,0.896258159530272,904945-FS1-4,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA,RO-has_definitional_manifestation
502813479,7/13/2014 16:23:31,,1321961257,7/13/2014 16:22:57,prodege,0.6149,28039757,GBR,L8,Southport,109.155.158.54,no_relation,168,143,,172,149,causes,0.896258159530272,904945-FS1-4,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA,RO-has_definitional_manifestation
502813479,7/13/2014 16:25:29,,1321962128,7/13/2014 16:24:55,rewardsspot,0.5812,24482174,GBR,H9,London,46.23.68.180,PAIN causes ANGINA,168,143,,172,149,causes,0.896258159530272,904945-FS1-4,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA,RO-has_definitional_manifestation
502813479,7/13/2014 16:35:19,,1321966408,7/13/2014 16:34:58,instagc,0.4853,25990856,USA,NV,Las Vegas,68.108.98.78,no_relation,168,143,,172,149,causes,0.896258159530272,904945-FS1-4,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA,RO-has_definitional_manifestation
502813479,7/13/2014 16:40:40,,1321968542,7/13/2014 16:40:07,instagc,0.5571,20183814,USA,"","",166.182.83.213,ANGINA causes PAIN,168,143,,172,149,causes,0.896258159530272,904945-FS1-4,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out ANGINA suggests that the PAIN is not ischemic.",PAIN,ANGINA,RO-has_definitional_manifestation
502813480,7/13/2014 15:34:36,,1321942722,7/13/2014 15:34:29,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,OSTEOARTHRITIS treats NAPROXEN,450,253,,464,261,treats,0.990147542976674,907732-FS1-2,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN,RO-may_treat
502813480,7/13/2014 15:43:11,,1321946089,7/13/2014 15:42:12,prodege,0.6736,27096445,GBR,H9,London,86.186.168.254,NAPROXEN treats OSTEOARTHRITIS,450,253,,464,261,treats,0.990147542976674,907732-FS1-2,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN,RO-may_treat
502813480,7/13/2014 16:01:11,,1321952955,7/13/2014 16:00:49,clixsense,0.6083,25402344,CAN,ON,Wawa,24.109.124.45,NAPROXEN treats OSTEOARTHRITIS,450,253,,464,261,treats,0.990147542976674,907732-FS1-2,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN,RO-may_treat
502813480,7/13/2014 16:23:51,,1321961422,7/13/2014 16:23:20,rewardsspot,0.5812,24482174,GBR,H9,London,46.23.68.180,NAPROXEN treats OSTEOARTHRITIS,450,253,,464,261,treats,0.990147542976674,907732-FS1-2,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN,RO-may_treat
502813480,7/13/2014 16:35:55,,1321966711,7/13/2014 16:35:36,instagc,0.4853,25990856,USA,NV,Las Vegas,68.108.98.78,NAPROXEN treats OSTEOARTHRITIS,450,253,,464,261,treats,0.990147542976674,907732-FS1-2,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN,RO-may_treat
502813480,7/13/2014 16:40:40,,1321968541,7/13/2014 16:40:07,instagc,0.5571,20183814,USA,"","",166.182.83.213,NAPROXEN treats OSTEOARTHRITIS,450,253,,464,261,treats,0.990147542976674,907732-FS1-2,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN,RO-may_treat
502813480,7/13/2014 16:46:45,,1321970573,7/13/2014 16:45:57,instagc,0.5933,24252915,GBR,B7,Bristol,77.98.139.82,NAPROXEN treats OSTEOARTHRITIS,450,253,,464,261,treats,0.990147542976674,907732-FS1-2,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in OSTEOARTHRITIS  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",OSTEOARTHRITIS,NAPROXEN,RO-may_treat
502813481,7/13/2014 15:25:54,,1321939127,7/13/2014 15:25:29,clixsense,0.9167,15189335,GBR,K3,Peterborough,81.156.166.189,METHACHOLINE causes BRONCHIAL HYPERREACTIVITY,90,119,,115,131,causes,0.894427190999916,906914-FS1-4,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE,RO-may_diagnose
502813481,7/13/2014 15:37:17,,1321943906,7/13/2014 15:37:10,neodev,0.5278,25224036,CAN,ON,Sudbury,67.204.218.187,BRONCHIAL HYPERREACTIVITY causes METHACHOLINE,90,119,,115,131,causes,0.894427190999916,906914-FS1-4,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE,RO-may_diagnose
502813481,7/13/2014 15:37:47,,1321944044,7/13/2014 15:37:10,clixsense,0.7361,27871219,NLD,07,Amsterdam,87.210.207.223,METHACHOLINE causes BRONCHIAL HYPERREACTIVITY,90,119,,115,131,causes,0.894427190999916,906914-FS1-4,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE,RO-may_diagnose
502813481,7/13/2014 15:39:32,,1321944704,7/13/2014 15:39:14,instagc,0.7153,18960682,GBR,"","",86.29.147.112,no_relation,90,119,,115,131,causes,0.894427190999916,906914-FS1-4,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE,RO-may_diagnose
502813481,7/13/2014 15:42:29,,1321945843,7/13/2014 15:42:21,neodev,0.6488,17610000,GBR,I2,Manchester,90.200.140.201,BRONCHIAL HYPERREACTIVITY causes METHACHOLINE,90,119,,115,131,causes,0.894427190999916,906914-FS1-4,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE,RO-may_diagnose
502813481,7/13/2014 16:24:41,,1321961816,7/13/2014 16:24:04,prodege,0.675,19192508,USA,OK,Broken Arrow,70.177.111.89,no_relation,90,119,,115,131,causes,0.894427190999916,906914-FS1-4,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE,RO-may_diagnose
502813481,7/13/2014 16:40:05,,1321968319,7/13/2014 16:39:39,instagc,0.5571,20183814,USA,"","",166.182.83.213,no_relation,90,119,,115,131,causes,0.894427190999916,906914-FS1-4,"The duration and severity of BA, the presence of allergy determined by skin tests and the BRONCHIAL HYPERREACTIVITY to METHACHOLINE inhalation challenge were observed on the first day of study.",BRONCHIAL HYPERREACTIVITY,METHACHOLINE,RO-may_diagnose
502813482,7/13/2014 15:26:34,,1321939397,7/13/2014 15:25:55,clixsense,0.9167,15189335,GBR,K3,Peterborough,81.156.166.189,no_relation,18,48,,39,57,causes,0.342997170285018,902335-FS1-4,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS,RO-disease_has_primary_anatomic_site
502813482,7/13/2014 16:00:48,,1321952812,7/13/2014 16:00:24,clixsense,0.6083,25402344,CAN,ON,Wawa,24.109.124.45,PRIMARY SKIN DISEASES causes PSORIASIS,18,48,,39,57,causes,0.342997170285018,902335-FS1-4,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS,RO-disease_has_primary_anatomic_site
502813482,7/13/2014 16:20:31,,1321960249,7/13/2014 16:19:52,prodege,0.6149,28039757,GBR,L8,Southport,109.155.158.54,no_relation,18,48,,39,57,causes,0.342997170285018,902335-FS1-4,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS,RO-disease_has_primary_anatomic_site
502813482,7/13/2014 16:24:04,,1321961536,7/13/2014 16:23:37,prodege,0.675,19192508,USA,OK,Broken Arrow,70.177.111.89,no_relation,18,48,,39,57,causes,0.342997170285018,902335-FS1-4,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS,RO-disease_has_primary_anatomic_site
502813482,7/13/2014 16:28:50,,1321963616,7/13/2014 16:27:56,elite,0.304,28276268,USA,CA,San Diego,76.88.95.100,PRIMARY SKIN DISEASES causes PSORIASIS,18,48,,39,57,causes,0.342997170285018,902335-FS1-4,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS,RO-disease_has_primary_anatomic_site
502813482,7/13/2014 16:40:05,,1321968313,7/13/2014 16:39:39,instagc,0.5571,20183814,USA,"","",166.182.83.213,no_relation,18,48,,39,57,causes,0.342997170285018,902335-FS1-4,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS,RO-disease_has_primary_anatomic_site
502813482,7/13/2014 16:45:31,,1321970064,7/13/2014 16:44:49,instagc,0.5933,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,18,48,,39,57,causes,0.342997170285018,902335-FS1-4,"On the other hand PRIMARY SKIN DISEASES such as PSORIASIS atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",PRIMARY SKIN DISEASES,PSORIASIS,RO-disease_has_primary_anatomic_site
502813483,7/13/2014 15:38:40,,1321944391,7/13/2014 15:38:22,instagc,0.7153,18960682,GBR,"","",86.29.147.112,no_relation,64,8,,95,40,causes,0.625543242171224,901949-FS1-4,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT),RO-disease_has_finding
502813483,7/13/2014 15:58:44,,1321951994,7/13/2014 15:58:30,clixsense,0.6639,27793793,GBR,C5,Chester,151.230.27.155,no_relation,64,8,,95,40,causes,0.625543242171224,901949-FS1-4,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT),RO-disease_has_finding
502813483,7/13/2014 16:01:11,,1321952957,7/13/2014 16:00:49,clixsense,0.6083,25402344,CAN,ON,Wawa,24.109.124.45,PRIMARY ACQUIRED THROMBOCYTOSES causes (ESSENTIAL THROMBOCYTHAEMIA (PT),64,8,,95,40,causes,0.625543242171224,901949-FS1-4,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT),RO-disease_has_finding
502813483,7/13/2014 16:21:47,,1321960662,7/13/2014 16:21:14,prodege,0.6149,28039757,GBR,L8,Southport,109.155.158.54,no_relation,64,8,,95,40,causes,0.625543242171224,901949-FS1-4,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT),RO-disease_has_finding
502813483,7/13/2014 16:24:50,,1321961876,7/13/2014 16:23:56,rewardsspot,0.5812,24482174,GBR,H9,London,46.23.68.180,no_relation,64,8,,95,40,causes,0.625543242171224,901949-FS1-4,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT),RO-disease_has_finding
502813483,7/13/2014 16:28:50,,1321963611,7/13/2014 16:27:56,elite,0.304,28276268,USA,CA,San Diego,76.88.95.100,(ESSENTIAL THROMBOCYTHAEMIA (PT) causes PRIMARY ACQUIRED THROMBOCYTOSES,64,8,,95,40,causes,0.625543242171224,901949-FS1-4,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT),RO-disease_has_finding
502813483,7/13/2014 16:39:39,,1321968133,7/13/2014 16:39:21,instagc,0.5571,20183814,USA,"","",166.182.83.213,PRIMARY ACQUIRED THROMBOCYTOSES causes (ESSENTIAL THROMBOCYTHAEMIA (PT),64,8,,95,40,causes,0.625543242171224,901949-FS1-4,Primary (ESSENTIAL THROMBOCYTHAEMIA (PT) is one of the forms of PRIMARY ACQUIRED THROMBOCYTOSES,PRIMARY ACQUIRED THROMBOCYTOSES,(ESSENTIAL THROMBOCYTHAEMIA (PT),RO-disease_has_finding
502813484,7/13/2014 15:36:46,,1321943660,7/13/2014 15:36:40,neodev,0.5278,25224036,CAN,ON,Sudbury,67.204.218.187,TINEA PEDIS treats SULCONAZOLE NITRATE 1% CREAM,36,53,,47,81,treats,0.993883734673619,907886-FS1-2,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM,RO-may_treat
502813484,7/13/2014 15:41:09,,1321945332,7/13/2014 15:40:31,instagc,0.7889,28301350,GBR,K4,Plymouth,89.241.102.134,SULCONAZOLE NITRATE 1% CREAM treats TINEA PEDIS,36,53,,47,81,treats,0.993883734673619,907886-FS1-2,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM,RO-may_treat
502813484,7/13/2014 15:45:42,,1321946999,7/13/2014 15:45:10,prodege,0.6736,27096445,GBR,H9,London,86.186.168.254,SULCONAZOLE NITRATE 1% CREAM treats TINEA PEDIS,36,53,,47,81,treats,0.993883734673619,907886-FS1-2,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM,RO-may_treat
502813484,7/13/2014 15:50:04,,1321948521,7/13/2014 15:49:31,uniquerewards,0.6917,20281752,GBR,M1,Slough,86.136.105.36,SULCONAZOLE NITRATE 1% CREAM treats TINEA PEDIS,36,53,,47,81,treats,0.993883734673619,907886-FS1-2,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM,RO-may_treat
502813484,7/13/2014 15:58:01,,1321951692,7/13/2014 15:57:48,clixsense,0.6639,27793793,GBR,C5,Chester,151.230.27.155,SULCONAZOLE NITRATE 1% CREAM treats TINEA PEDIS,36,53,,47,81,treats,0.993883734673619,907886-FS1-2,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM,RO-may_treat
502813484,7/13/2014 16:01:39,,1321953154,7/13/2014 16:01:12,clixsense,0.6083,25402344,CAN,ON,Wawa,24.109.124.45,SULCONAZOLE NITRATE 1% CREAM treats TINEA PEDIS,36,53,,47,81,treats,0.993883734673619,907886-FS1-2,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM,RO-may_treat
502813484,7/13/2014 16:09:01,,1321955916,7/13/2014 16:07:46,bitcoinget,0.4236,27786287,USA,FL,Jacksonville,76.106.186.209,SULCONAZOLE NITRATE 1% CREAM treats TINEA PEDIS,36,53,,47,81,treats,0.993883734673619,907886-FS1-2,"Woscoff A, Carabeli S. Treatment of TINEA PEDIS with SULCONAZOLE NITRATE 1% CREAM or miconazole nitrate 2% cream.",TINEA PEDIS,SULCONAZOLE NITRATE 1% CREAM,RO-may_treat
502813485,7/13/2014 15:26:34,,1321939398,7/13/2014 15:25:55,clixsense,0.9167,15189335,GBR,K3,Peterborough,81.156.166.189,PRIMARY MENINGEAL MELANOMA causes NEUROLOGICAL SYMPTOMS,66,103,,87,129,causes,0.970142500145332,902605-FS1-4,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA,RO-disease_may_have_finding
502813485,7/13/2014 15:58:56,,1321952072,7/13/2014 15:58:46,clixsense,0.6639,27793793,GBR,C5,Chester,151.230.27.155,no_relation,66,103,,87,129,causes,0.970142500145332,902605-FS1-4,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA,RO-disease_may_have_finding
502813485,7/13/2014 16:02:02,,1321953272,7/13/2014 16:01:40,clixsense,0.6083,25402344,CAN,ON,Wawa,24.109.124.45,PRIMARY MENINGEAL MELANOMA causes NEUROLOGICAL SYMPTOMS,66,103,,87,129,causes,0.970142500145332,902605-FS1-4,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA,RO-disease_may_have_finding
502813485,7/13/2014 16:14:09,,1321957962,7/13/2014 16:13:46,neodev,0.6407,14861092,GBR,I2,Manchester,90.194.137.76,PRIMARY MENINGEAL MELANOMA causes NEUROLOGICAL SYMPTOMS,66,103,,87,129,causes,0.970142500145332,902605-FS1-4,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA,RO-disease_may_have_finding
502813485,7/13/2014 16:20:23,,1321960215,7/13/2014 16:19:33,rewardsspot,0.5812,24482174,GBR,H9,London,46.23.68.180,NEUROLOGICAL SYMPTOMS causes PRIMARY MENINGEAL MELANOMA,66,103,,87,129,causes,0.970142500145332,902605-FS1-4,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA,RO-disease_may_have_finding
502813485,7/13/2014 16:21:47,,1321960661,7/13/2014 16:21:14,prodege,0.6149,28039757,GBR,L8,Southport,109.155.158.54,PRIMARY MENINGEAL MELANOMA causes NEUROLOGICAL SYMPTOMS,66,103,,87,129,causes,0.970142500145332,902605-FS1-4,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA,RO-disease_may_have_finding
502813485,7/13/2014 16:25:12,,1321962004,7/13/2014 16:24:42,prodege,0.675,19192508,USA,OK,Broken Arrow,70.177.111.89,PRIMARY MENINGEAL MELANOMA causes NEUROLOGICAL SYMPTOMS,66,103,,87,129,causes,0.970142500145332,902605-FS1-4,We describe a patient with cutaneous melanosis who presented with NEUROLOGICAL SYMPTOMS due to a large PRIMARY MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,PRIMARY MENINGEAL MELANOMA,RO-disease_may_have_finding
502813486,7/13/2014 15:28:38,,1321940283,7/13/2014 15:28:02,clixsense,0.9167,15189335,GBR,K3,Peterborough,81.156.166.189,FLUOXETINE treats OBSESSIVE COMPULSIVE DISORDER,82,51,,111,61,treats,0.987878339907213,907730-FS1-2,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE,RO-may_treat
502813486,7/13/2014 15:34:05,,1321942551,7/13/2014 15:33:56,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,FLUOXETINE treats OBSESSIVE COMPULSIVE DISORDER,82,51,,111,61,treats,0.987878339907213,907730-FS1-2,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE,RO-may_treat
502813486,7/13/2014 15:37:09,,1321943826,7/13/2014 15:37:02,neodev,0.5278,25224036,CAN,ON,Sudbury,67.204.218.187,OBSESSIVE COMPULSIVE DISORDER treats FLUOXETINE,82,51,,111,61,treats,0.987878339907213,907730-FS1-2,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE,RO-may_treat
502813486,7/13/2014 15:50:04,,1321948524,7/13/2014 15:49:31,uniquerewards,0.6917,20281752,GBR,M1,Slough,86.136.105.36,FLUOXETINE treats OBSESSIVE COMPULSIVE DISORDER,82,51,,111,61,treats,0.987878339907213,907730-FS1-2,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE,RO-may_treat
502813486,7/13/2014 16:02:02,,1321953267,7/13/2014 16:01:40,clixsense,0.6083,25402344,CAN,ON,Wawa,24.109.124.45,FLUOXETINE treats OBSESSIVE COMPULSIVE DISORDER,82,51,,111,61,treats,0.987878339907213,907730-FS1-2,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE,RO-may_treat
502813486,7/13/2014 16:09:01,,1321955915,7/13/2014 16:07:46,bitcoinget,0.4236,27786287,USA,FL,Jacksonville,76.106.186.209,FLUOXETINE treats OBSESSIVE COMPULSIVE DISORDER,82,51,,111,61,treats,0.987878339907213,907730-FS1-2,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE,RO-may_treat
502813486,7/13/2014 16:14:50,,1321958277,7/13/2014 16:14:30,neodev,0.6407,14861092,GBR,I2,Manchester,90.194.137.76,FLUOXETINE treats OBSESSIVE COMPULSIVE DISORDER,82,51,,111,61,treats,0.987878339907213,907730-FS1-2,"Fontaine R, Chouinard G. An open clinical trial of FLUOXETINE in the treatment of OBSESSIVE COMPULSIVE DISORDER",OBSESSIVE COMPULSIVE DISORDER,FLUOXETINE,RO-may_treat
502813487,7/13/2014 15:28:38,,1321940276,7/13/2014 15:28:02,clixsense,0.9167,15189335,GBR,K3,Peterborough,81.156.166.189,WORK RELATED ALLERGY causes DELAYED TYPE HYPERSENSITIVITIES,61,106,,81,137,causes,0.424264068711929,900222-FS1-4,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES,RO-cause_of
502813487,7/13/2014 15:37:09,,1321943817,7/13/2014 15:36:24,clixsense,0.7361,27871219,NLD,07,Amsterdam,87.210.207.223,WORK RELATED ALLERGY causes DELAYED TYPE HYPERSENSITIVITIES,61,106,,81,137,causes,0.424264068711929,900222-FS1-4,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES,RO-cause_of
502813487,7/13/2014 15:52:04,,1321949343,7/13/2014 15:51:25,uniquerewards,0.6917,20281752,GBR,M1,Slough,86.136.105.36,DELAYED TYPE HYPERSENSITIVITIES causes WORK RELATED ALLERGY,61,106,,81,137,causes,0.424264068711929,900222-FS1-4,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES,RO-cause_of
502813487,7/13/2014 16:10:58,,1321956641,7/13/2014 16:10:43,bitcoinget,0.4236,27786287,USA,FL,Jacksonville,76.106.186.209,no_relation,61,106,,81,137,causes,0.424264068711929,900222-FS1-4,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES,RO-cause_of
502813487,7/13/2014 16:19:28,,1321959984,7/13/2014 16:18:29,clixsense,0.2,25595227,CAN,SK,North Battleford,24.72.96.119,no_relation,61,106,,81,137,causes,0.424264068711929,900222-FS1-4,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES,RO-cause_of
502813487,7/13/2014 16:35:34,,1321966481,7/13/2014 16:35:21,instagc,0.4853,25990856,USA,NV,Las Vegas,68.108.98.78,no_relation,61,106,,81,137,causes,0.424264068711929,900222-FS1-4,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES,RO-cause_of
502813487,7/13/2014 16:39:20,,1321968061,7/13/2014 16:38:55,instagc,0.5571,20183814,USA,"","",166.182.83.213,WORK RELATED ALLERGY causes DELAYED TYPE HYPERSENSITIVITIES,61,106,,81,137,causes,0.424264068711929,900222-FS1-4,"In this chapter, various methods of protecting a worker from WORK RELATED ALLERGY including immediate and DELAYED TYPE HYPERSENSITIVITIES are considered and reviewed.",WORK RELATED ALLERGY,DELAYED TYPE HYPERSENSITIVITIES,RO-cause_of
502813488,7/13/2014 15:34:46,,1321942758,7/13/2014 15:34:37,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,ANTIANGINAL EFFICACY diagnosed by ANGINA DIARES,39,0,,52,20,diagnosed by,0.845154254728516,907376-FS1-13,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY,RO-may_prevent
502813488,7/13/2014 15:36:46,,1321943659,7/13/2014 15:36:40,neodev,0.5278,25224036,CAN,ON,Sudbury,67.204.218.187,ANTIANGINAL EFFICACY diagnosed by ANGINA DIARES,39,0,,52,20,diagnosed by,0.845154254728516,907376-FS1-13,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY,RO-may_prevent
502813488,7/13/2014 15:37:16,,1321943891,7/13/2014 15:36:49,neodev,0.7292,28336203,USA,PA,Harrisburg,50.149.53.150,no_relation,39,0,,52,20,diagnosed by,0.845154254728516,907376-FS1-13,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY,RO-may_prevent
502813488,7/13/2014 15:41:32,,1321945500,7/13/2014 15:41:10,instagc,0.7889,28301350,GBR,K4,Plymouth,89.241.102.134,ANTIANGINAL EFFICACY diagnosed by ANGINA DIARES,39,0,,52,20,diagnosed by,0.845154254728516,907376-FS1-13,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY,RO-may_prevent
502813488,7/13/2014 15:45:09,,1321946808,7/13/2014 15:44:37,prodege,0.6736,27096445,GBR,H9,London,86.186.168.254,no_relation,39,0,,52,20,diagnosed by,0.845154254728516,907376-FS1-13,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY,RO-may_prevent
502813488,7/13/2014 16:00:48,,1321952813,7/13/2014 16:00:24,clixsense,0.6083,25402344,CAN,ON,Wawa,24.109.124.45,ANTIANGINAL EFFICACY diagnosed by ANGINA DIARES,39,0,,52,20,diagnosed by,0.845154254728516,907376-FS1-13,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY,RO-may_prevent
502813488,7/13/2014 16:22:14,,1321960843,7/13/2014 16:21:48,prodege,0.6149,28039757,GBR,L8,Southport,109.155.158.54,no_relation,39,0,,52,20,diagnosed by,0.845154254728516,907376-FS1-13,"ANTIANGINAL EFFICACY was assessed with ANGINA DIARES investigators, and patients global evaluations and with treadmill exercise test during placebo run in period and after 8 weeks of the therapy.",ANGINA DIARES,ANTIANGINAL EFFICACY,RO-may_prevent
502813489,7/13/2014 15:34:16,,1321942634,7/13/2014 15:34:06,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,PURTSCHER'S RETINOPATHY causes TRAUMA,0,80,,23,86,causes,0.843274042711568,900463-FS1-4,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA,RO-cause_of
502813489,7/13/2014 15:35:16,,1321942982,7/13/2014 15:34:54,clixsense,0.9167,15189335,GBR,K3,Peterborough,81.156.166.189,TRAUMA causes PURTSCHER'S RETINOPATHY,0,80,,23,86,causes,0.843274042711568,900463-FS1-4,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA,RO-cause_of
502813489,7/13/2014 15:36:48,,1321943668,7/13/2014 15:36:25,neodev,0.7292,28336203,USA,PA,Harrisburg,50.149.53.150,no_relation,0,80,,23,86,causes,0.843274042711568,900463-FS1-4,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA,RO-cause_of
502813489,7/13/2014 15:37:17,,1321943907,7/13/2014 15:37:10,neodev,0.5278,25224036,CAN,ON,Sudbury,67.204.218.187,TRAUMA causes PURTSCHER'S RETINOPATHY,0,80,,23,86,causes,0.843274042711568,900463-FS1-4,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA,RO-cause_of
502813489,7/13/2014 15:38:46,,1321944437,7/13/2014 15:38:14,clixsense,0.7361,27871219,NLD,07,Amsterdam,87.210.207.223,TRAUMA causes PURTSCHER'S RETINOPATHY,0,80,,23,86,causes,0.843274042711568,900463-FS1-4,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA,RO-cause_of
502813489,7/13/2014 15:40:30,,1321945067,7/13/2014 15:39:53,instagc,0.7889,28301350,GBR,K4,Plymouth,89.241.102.134,TRAUMA causes PURTSCHER'S RETINOPATHY,0,80,,23,86,causes,0.843274042711568,900463-FS1-4,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA,RO-cause_of
502813489,7/13/2014 15:41:57,,1321945665,7/13/2014 15:41:44,neodev,0.6488,17610000,GBR,I2,Manchester,90.200.140.201,PURTSCHER'S RETINOPATHY causes TRAUMA,0,80,,23,86,causes,0.843274042711568,900463-FS1-4,"PURTSCHER'S RETINOPATHY is a rare condition, seen in patients with a history of TRAUMA",PURTSCHER'S RETINOPATHY,TRAUMA,RO-cause_of
502813490,7/13/2014 16:12:50,,1321957458,7/13/2014 16:12:22,fusioncash,0.6208,22139728,USA,"","",66.67.91.242,no_relation,89,28,,119,50,causes,0.596284793999944,901753-FS1-4,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC),RO-disease_has_finding
502813490,7/13/2014 16:13:44,,1321957791,7/13/2014 16:13:19,neodev,0.6407,14861092,GBR,I2,Manchester,90.194.137.76,NEUROENDOCRINE DIFFERENTIATION causes LUNG CARCINOMAS (SCLC),89,28,,119,50,causes,0.596284793999944,901753-FS1-4,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC),RO-disease_has_finding
502813490,7/13/2014 16:34:57,,1321966251,7/13/2014 16:34:41,instagc,0.4853,25990856,USA,NV,Las Vegas,68.108.98.78,no_relation,89,28,,119,50,causes,0.596284793999944,901753-FS1-4,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC),RO-disease_has_finding
502813490,7/13/2014 16:47:14,,1321970810,7/13/2014 16:46:46,instagc,0.5933,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,89,28,,119,50,causes,0.596284793999944,901753-FS1-4,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC),RO-disease_has_finding
502813490,7/13/2014 16:48:10,,1321971147,7/13/2014 16:47:46,neodev,0.7345,27597779,CAN,AB,Calgary,68.146.86.137,no_relation,89,28,,119,50,causes,0.596284793999944,901753-FS1-4,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC),RO-disease_has_finding
502813490,7/13/2014 17:00:25,,1321975325,7/13/2014 16:59:11,clixsense,0.5437,28037714,GBR,I4,Mitcham,94.4.232.118,LUNG CARCINOMAS (SCLC) causes NEUROENDOCRINE DIFFERENTIATION,89,28,,119,50,causes,0.596284793999944,901753-FS1-4,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC),RO-disease_has_finding
502813490,7/13/2014 17:05:41,,1321976960,7/13/2014 17:05:18,clixsense,0.5,21917173,CAN,"","",24.71.41.51,no_relation,89,28,,119,50,causes,0.596284793999944,901753-FS1-4,In most cases of small cell LUNG CARCINOMAS (SCLC) phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be identified by monoclonal (MOC) antibody based immunohistological procedures.,NEUROENDOCRINE DIFFERENTIATION,LUNG CARCINOMAS (SCLC),RO-disease_has_finding
502813491,7/13/2014 15:35:16,,1321942979,7/13/2014 15:34:54,clixsense,0.9167,15189335,GBR,K3,Peterborough,81.156.166.189,GASTROINTESTINAL TRACT is location of INFLAMMATORY BOWEL DISEASE,124,9,,146,35,is location of,0.7184212081071,905078-FS1-9,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,RO-has_finding_site
502813491,7/13/2014 15:36:48,,1321943678,7/13/2014 15:36:25,neodev,0.7292,28336203,USA,PA,Harrisburg,50.149.53.150,GASTROINTESTINAL TRACT is location of INFLAMMATORY BOWEL DISEASE,124,9,,146,35,is location of,0.7184212081071,905078-FS1-9,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,RO-has_finding_site
502813491,7/13/2014 15:39:19,,1321944662,7/13/2014 15:38:51,instagc,0.7889,28301350,GBR,K4,Plymouth,89.241.102.134,GASTROINTESTINAL TRACT is location of INFLAMMATORY BOWEL DISEASE,124,9,,146,35,is location of,0.7184212081071,905078-FS1-9,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,RO-has_finding_site
502813491,7/13/2014 15:43:11,,1321946090,7/13/2014 15:42:12,prodege,0.6736,27096445,GBR,H9,London,86.186.168.254,GASTROINTESTINAL TRACT is location of INFLAMMATORY BOWEL DISEASE,124,9,,146,35,is location of,0.7184212081071,905078-FS1-9,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,RO-has_finding_site
502813491,7/13/2014 16:03:33,,1321953806,7/13/2014 16:02:32,elite,0.75,28397222,GBR,"","",31.49.231.211,GASTROINTESTINAL TRACT is location of INFLAMMATORY BOWEL DISEASE,124,9,,146,35,is location of,0.7184212081071,905078-FS1-9,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,RO-has_finding_site
502813491,7/13/2014 16:10:38,,1321956550,7/13/2014 16:09:44,fusioncash,0.6208,22139728,USA,"","",66.67.91.242,INFLAMMATORY BOWEL DISEASE is location of GASTROINTESTINAL TRACT,124,9,,146,35,is location of,0.7184212081071,905078-FS1-9,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,RO-has_finding_site
502813491,7/13/2014 16:29:48,,1321964095,7/13/2014 16:28:52,elite,0.304,28276268,USA,CA,San Diego,76.88.95.100,INFLAMMATORY BOWEL DISEASE is location of GASTROINTESTINAL TRACT,124,9,,146,35,is location of,0.7184212081071,905078-FS1-9,The term INFLAMMATORY BOWEL DISEASE (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of GASTROINTESTINAL TRACT,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,RO-has_finding_site
502813492,7/13/2014 15:25:54,,1321939135,7/13/2014 15:25:29,clixsense,0.9167,15189335,GBR,K3,Peterborough,81.156.166.189,PREECLAMPSIA causes PREGNANCY COMPLICATIONS,121,153,,144,165,causes,0.811107105653813,901876-FS1-4,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA,RO-disease_has_finding
502813492,7/13/2014 15:34:46,,1321942757,7/13/2014 15:34:37,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,PREECLAMPSIA causes PREGNANCY COMPLICATIONS,121,153,,144,165,causes,0.811107105653813,901876-FS1-4,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA,RO-disease_has_finding
502813492,7/13/2014 15:36:53,,1321943697,7/13/2014 15:36:46,neodev,0.5278,25224036,CAN,ON,Sudbury,67.204.218.187,PREGNANCY COMPLICATIONS causes PREECLAMPSIA,121,153,,144,165,causes,0.811107105653813,901876-FS1-4,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA,RO-disease_has_finding
502813492,7/13/2014 15:42:13,,1321945759,7/13/2014 15:42:05,neodev,0.6488,17610000,GBR,I2,Manchester,90.200.140.201,PREGNANCY COMPLICATIONS causes PREECLAMPSIA,121,153,,144,165,causes,0.811107105653813,901876-FS1-4,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA,RO-disease_has_finding
502813492,7/13/2014 15:58:56,,1321952074,7/13/2014 15:58:46,clixsense,0.6639,27793793,GBR,C5,Chester,151.230.27.155,PREECLAMPSIA causes PREGNANCY COMPLICATIONS,121,153,,144,165,causes,0.811107105653813,901876-FS1-4,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA,RO-disease_has_finding
502813492,7/13/2014 16:02:20,,1321953348,7/13/2014 16:02:03,clixsense,0.6083,25402344,CAN,ON,Wawa,24.109.124.45,PREGNANCY COMPLICATIONS causes PREECLAMPSIA,121,153,,144,165,causes,0.811107105653813,901876-FS1-4,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA,RO-disease_has_finding
502813492,7/13/2014 16:10:23,,1321956461,7/13/2014 16:10:03,bitcoinget,0.4236,27786287,USA,FL,Jacksonville,76.106.186.209,no_relation,121,153,,144,165,causes,0.811107105653813,901876-FS1-4,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in PREGNANCY COMPLICATIONS such as PREECLAMPSIA",PREGNANCY COMPLICATIONS,PREECLAMPSIA,RO-disease_has_finding
502813493,7/13/2014 15:33:55,,1321942498,7/13/2014 15:33:40,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,CORNEAL NERVES AND HYPERTENSION causes PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA,127,226,,158,270,causes,0.821994936526786,902547-FS1-4,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA,RO-disease_may_have_finding
502813493,7/13/2014 15:42:37,,1321945870,7/13/2014 15:42:29,neodev,0.6488,17610000,GBR,I2,Manchester,90.200.140.201,CORNEAL NERVES AND HYPERTENSION causes PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA,127,226,,158,270,causes,0.821994936526786,902547-FS1-4,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA,RO-disease_may_have_finding
502813493,7/13/2014 15:51:24,,1321949071,7/13/2014 15:50:54,uniquerewards,0.6917,20281752,GBR,M1,Slough,86.136.105.36,no_relation,127,226,,158,270,causes,0.821994936526786,902547-FS1-4,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA,RO-disease_may_have_finding
502813493,7/13/2014 16:10:01,,1321956280,7/13/2014 16:09:01,bitcoinget,0.4236,27786287,USA,FL,Jacksonville,76.106.186.209,no_relation,127,226,,158,270,causes,0.821994936526786,902547-FS1-4,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA,RO-disease_may_have_finding
502813493,7/13/2014 16:24:50,,1321961884,7/13/2014 16:23:56,rewardsspot,0.5812,24482174,GBR,H9,London,46.23.68.180,no_relation,127,226,,158,270,causes,0.821994936526786,902547-FS1-4,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA,RO-disease_may_have_finding
502813493,7/13/2014 16:30:45,,1321964541,7/13/2014 16:30:23,elite,0.304,28276268,USA,CA,San Diego,76.88.95.100,CORNEAL NERVES AND HYPERTENSION causes PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA,127,226,,158,270,causes,0.821994936526786,902547-FS1-4,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA,RO-disease_may_have_finding
502813493,7/13/2014 16:34:40,,1321966148,7/13/2014 16:34:17,instagc,0.4853,25990856,USA,NV,Las Vegas,68.108.98.78,no_relation,127,226,,158,270,causes,0.821994936526786,902547-FS1-4,"A 29 year old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic CORNEAL NERVES AND HYPERTENSION was found at operation to have medullary carcinoma of the thyroid, PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA",CORNEAL NERVES AND HYPERTENSION,PARATHYROID HYPERPLASIA AND PHEOCHROMOCYTOMA,RO-disease_may_have_finding
502813494,7/13/2014 15:35:55,,1321943260,7/13/2014 15:35:25,clixsense,0.7361,27871219,NLD,07,Amsterdam,87.210.207.223,no_relation,273,209,,278,217,causes,0.883883476483184,903891-FS1-4,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE,RO-has_causative_agent
502813494,7/13/2014 15:37:01,,1321943727,7/13/2014 15:36:54,neodev,0.5278,25224036,CAN,ON,Sudbury,67.204.218.187,OVERDOSE causes DRUGS,273,209,,278,217,causes,0.883883476483184,903891-FS1-4,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE,RO-has_causative_agent
502813494,7/13/2014 15:46:22,,1321947181,7/13/2014 15:45:43,prodege,0.6736,27096445,GBR,H9,London,86.186.168.254,DRUGS causes OVERDOSE,273,209,,278,217,causes,0.883883476483184,903891-FS1-4,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE,RO-has_causative_agent
502813494,7/13/2014 16:03:33,,1321953807,7/13/2014 16:02:32,elite,0.75,28397222,GBR,"","",31.49.231.211,DRUGS causes OVERDOSE,273,209,,278,217,causes,0.883883476483184,903891-FS1-4,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE,RO-has_causative_agent
502813494,7/13/2014 16:12:06,,1321957134,7/13/2014 16:11:50,fusioncash,0.6208,22139728,USA,"","",66.67.91.242,DRUGS causes OVERDOSE,273,209,,278,217,causes,0.883883476483184,903891-FS1-4,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE,RO-has_causative_agent
502813494,7/13/2014 16:26:13,,1321962424,7/13/2014 16:25:35,rewardsspot,0.5812,24482174,GBR,H9,London,46.23.68.180,DRUGS causes OVERDOSE,273,209,,278,217,causes,0.883883476483184,903891-FS1-4,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE,RO-has_causative_agent
502813494,7/13/2014 16:29:48,,1321964096,7/13/2014 16:28:52,elite,0.304,28276268,USA,CA,San Diego,76.88.95.100,OVERDOSE causes DRUGS,273,209,,278,217,causes,0.883883476483184,903891-FS1-4,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both OVERDOSE and coadministration of macrolide antibiotics or other DRUGS that interfere with their elimination.,DRUGS,OVERDOSE,RO-has_causative_agent
502813495,7/13/2014 15:37:09,,1321943819,7/13/2014 15:36:24,clixsense,0.7361,27871219,NLD,07,Amsterdam,87.210.207.223,PROBIOTIC BACTERIA treats CARIES,75,110,,93,116,treats,0.625543242171224,903916-FS1-2,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES,RO-has_causative_agent
502813495,7/13/2014 15:38:40,,1321944379,7/13/2014 15:38:22,instagc,0.7153,18960682,GBR,"","",86.29.147.112,no_relation,75,110,,93,116,treats,0.625543242171224,903916-FS1-2,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES,RO-has_causative_agent
502813495,7/13/2014 15:41:09,,1321945333,7/13/2014 15:40:31,instagc,0.7889,28301350,GBR,K4,Plymouth,89.241.102.134,PROBIOTIC BACTERIA treats CARIES,75,110,,93,116,treats,0.625543242171224,903916-FS1-2,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES,RO-has_causative_agent
502813495,7/13/2014 16:00:23,,1321952627,7/13/2014 15:59:48,clixsense,0.6083,25402344,CAN,ON,Wawa,24.109.124.45,PROBIOTIC BACTERIA treats CARIES,75,110,,93,116,treats,0.625543242171224,903916-FS1-2,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES,RO-has_causative_agent
502813495,7/13/2014 16:11:02,,1321956655,7/13/2014 16:10:58,bitcoinget,0.4236,27786287,USA,FL,Jacksonville,76.106.186.209,no_relation,75,110,,93,116,treats,0.625543242171224,903916-FS1-2,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES,RO-has_causative_agent
502813495,7/13/2014 16:11:18,,1321956741,7/13/2014 16:10:39,fusioncash,0.6208,22139728,USA,"","",66.67.91.242,no_relation,75,110,,93,116,treats,0.625543242171224,903916-FS1-2,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES,RO-has_causative_agent
502813495,7/13/2014 16:24:41,,1321961815,7/13/2014 16:24:04,prodege,0.675,19192508,USA,OK,Broken Arrow,70.177.111.89,PROBIOTIC BACTERIA treats CARIES,75,110,,93,116,treats,0.625543242171224,903916-FS1-2,The aim of this study was to evaluate the effect of milk supplemented with PROBIOTIC BACTERIA and fluoride on CARIES development and general health in preschool children.,PROBIOTIC BACTERIA,CARIES,RO-has_causative_agent
502813496,7/13/2014 15:34:05,,1321942552,7/13/2014 15:33:56,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,FVIII treats HEMOPHILIA A,76,26,,88,31,treats,0.962250448649376,906015-FS1-2,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII,RO-has_manifestation
502813496,7/13/2014 15:34:53,,1321942798,7/13/2014 15:34:23,clixsense,0.9167,15189335,GBR,K3,Peterborough,81.156.166.189,FVIII treats HEMOPHILIA A,76,26,,88,31,treats,0.962250448649376,906015-FS1-2,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII,RO-has_manifestation
502813496,7/13/2014 15:36:23,,1321943505,7/13/2014 15:35:56,clixsense,0.7361,27871219,NLD,07,Amsterdam,87.210.207.223,FVIII treats HEMOPHILIA A,76,26,,88,31,treats,0.962250448649376,906015-FS1-2,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII,RO-has_manifestation
502813496,7/13/2014 16:10:42,,1321956574,7/13/2014 16:10:24,bitcoinget,0.4236,27786287,USA,FL,Jacksonville,76.106.186.209,FVIII treats HEMOPHILIA A,76,26,,88,31,treats,0.962250448649376,906015-FS1-2,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII,RO-has_manifestation
502813496,7/13/2014 16:26:13,,1321962425,7/13/2014 16:25:35,rewardsspot,0.5812,24482174,GBR,H9,London,46.23.68.180,HEMOPHILIA A treats FVIII,76,26,,88,31,treats,0.962250448649376,906015-FS1-2,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII,RO-has_manifestation
502813496,7/13/2014 16:34:40,,1321966134,7/13/2014 16:34:17,instagc,0.4853,25990856,USA,NV,Las Vegas,68.108.98.78,FVIII treats HEMOPHILIA A,76,26,,88,31,treats,0.962250448649376,906015-FS1-2,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII,RO-has_manifestation
502813496,7/13/2014 16:47:14,,1321970811,7/13/2014 16:46:46,instagc,0.5933,24252915,GBR,B7,Bristol,77.98.139.82,FVIII treats HEMOPHILIA A,76,26,,88,31,treats,0.962250448649376,906015-FS1-2,"Replacement therapy using FVIII is the leading therapy in the management of HEMOPHILIA A However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",HEMOPHILIA A,FVIII,RO-has_manifestation
502813497,7/13/2014 15:36:04,,1321943329,7/13/2014 15:35:57,neodev,0.7292,28336203,USA,PA,Harrisburg,50.149.53.150,CELIAC DISEASE treats GLUTEN FREE DIET,17,51,,33,65,treats,0.984731927834662,903642-FS1-2,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE,RO-has_causative_agent
502813497,7/13/2014 15:36:39,,1321943619,7/13/2014 15:36:33,neodev,0.5278,25224036,CAN,ON,Sudbury,67.204.218.187,CELIAC DISEASE treats GLUTEN FREE DIET,17,51,,33,65,treats,0.984731927834662,903642-FS1-2,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE,RO-has_causative_agent
502813497,7/13/2014 15:39:32,,1321944687,7/13/2014 15:39:14,instagc,0.7153,18960682,GBR,"","",86.29.147.112,GLUTEN FREE DIET treats CELIAC DISEASE,17,51,,33,65,treats,0.984731927834662,903642-FS1-2,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE,RO-has_causative_agent
502813497,7/13/2014 15:42:20,,1321945804,7/13/2014 15:42:14,neodev,0.6488,17610000,GBR,I2,Manchester,90.200.140.201,GLUTEN FREE DIET treats CELIAC DISEASE,17,51,,33,65,treats,0.984731927834662,903642-FS1-2,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE,RO-has_causative_agent
502813497,7/13/2014 16:12:21,,1321957227,7/13/2014 16:12:07,fusioncash,0.6208,22139728,USA,"","",66.67.91.242,GLUTEN FREE DIET treats CELIAC DISEASE,17,51,,33,65,treats,0.984731927834662,903642-FS1-2,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE,RO-has_causative_agent
502813497,7/13/2014 16:23:37,,1321961311,7/13/2014 16:23:11,prodege,0.675,19192508,USA,OK,Broken Arrow,70.177.111.89,GLUTEN FREE DIET treats CELIAC DISEASE,17,51,,33,65,treats,0.984731927834662,903642-FS1-2,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE,RO-has_causative_agent
502813497,7/13/2014 16:23:51,,1321961421,7/13/2014 16:23:20,rewardsspot,0.5812,24482174,GBR,H9,London,46.23.68.180,GLUTEN FREE DIET treats CELIAC DISEASE,17,51,,33,65,treats,0.984731927834662,903642-FS1-2,"? Adherence to a GLUTEN FREE DIET in patients with CELIAC DISEASE can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",GLUTEN FREE DIET,CELIAC DISEASE,RO-has_causative_agent
502813498,7/13/2014 15:36:04,,1321943328,7/13/2014 15:35:57,neodev,0.7292,28336203,USA,PA,Harrisburg,50.149.53.150,ATOPIC causes ATOPIC DERMATITIS,77,77,,94,83,causes,0.625543242171224,900177-FS1-4,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC,RO-cause_of
502813498,7/13/2014 15:39:19,,1321944663,7/13/2014 15:38:51,instagc,0.7889,28301350,GBR,K4,Plymouth,89.241.102.134,no_relation,77,77,,94,83,causes,0.625543242171224,900177-FS1-4,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC,RO-cause_of
502813498,7/13/2014 15:50:53,,1321948830,7/13/2014 15:50:05,uniquerewards,0.6917,20281752,GBR,M1,Slough,86.136.105.36,no_relation,77,77,,94,83,causes,0.625543242171224,900177-FS1-4,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC,RO-cause_of
502813498,7/13/2014 16:01:39,,1321953149,7/13/2014 16:01:12,clixsense,0.6083,25402344,CAN,ON,Wawa,24.109.124.45,ATOPIC causes ATOPIC DERMATITIS,77,77,,94,83,causes,0.625543242171224,900177-FS1-4,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC,RO-cause_of
502813498,7/13/2014 16:38:38,,1321967782,7/13/2014 16:38:16,instagc,0.5571,20183814,USA,"","",166.182.83.213,no_relation,77,77,,94,83,causes,0.625543242171224,900177-FS1-4,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC,RO-cause_of
502813498,7/13/2014 16:44:23,,1321969624,7/13/2014 16:44:00,instagc,0.5933,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,77,77,,94,83,causes,0.625543242171224,900177-FS1-4,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC,RO-cause_of
502813498,7/13/2014 16:49:11,,1321971506,7/13/2014 16:48:41,neodev,0.7345,27597779,CAN,AB,Calgary,68.146.86.137,no_relation,77,77,,94,83,causes,0.625543242171224,900177-FS1-4,Sensitization to allergens of Japanese cedar pollen is known to cause canine ATOPIC DERMATITIS as approximately 10% of ATOPIC dogs in Japan were positive to the pollen allergen.,ATOPIC DERMATITIS,ATOPIC,RO-cause_of
502813499,7/13/2014 15:35:31,,1321943085,7/13/2014 15:35:17,clixsense,0.9167,15189335,GBR,K3,Peterborough,81.156.166.189,FLUORIDE causes DENTAL FLUOROSIS,489,242,,497,258,causes,0.898026510133875,903790-FS1-4,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS,RO-has_causative_agent
502813499,7/13/2014 15:36:53,,1321943696,7/13/2014 15:36:46,neodev,0.5278,25224036,CAN,ON,Sudbury,67.204.218.187,DENTAL FLUOROSIS causes FLUORIDE,489,242,,497,258,causes,0.898026510133875,903790-FS1-4,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS,RO-has_causative_agent
502813499,7/13/2014 15:42:13,,1321945758,7/13/2014 15:42:05,neodev,0.6488,17610000,GBR,I2,Manchester,90.200.140.201,FLUORIDE causes DENTAL FLUOROSIS,489,242,,497,258,causes,0.898026510133875,903790-FS1-4,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS,RO-has_causative_agent
502813499,7/13/2014 15:46:22,,1321947182,7/13/2014 15:45:43,prodege,0.6736,27096445,GBR,H9,London,86.186.168.254,FLUORIDE causes DENTAL FLUOROSIS,489,242,,497,258,causes,0.898026510133875,903790-FS1-4,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS,RO-has_causative_agent
502813499,7/13/2014 15:50:53,,1321948831,7/13/2014 15:50:05,uniquerewards,0.6917,20281752,GBR,M1,Slough,86.136.105.36,FLUORIDE causes DENTAL FLUOROSIS,489,242,,497,258,causes,0.898026510133875,903790-FS1-4,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS,RO-has_causative_agent
502813499,7/13/2014 16:44:48,,1321969851,7/13/2014 16:44:24,instagc,0.5933,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,489,242,,497,258,causes,0.898026510133875,903790-FS1-4,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS,RO-has_causative_agent
502813499,7/13/2014 16:49:11,,1321971505,7/13/2014 16:48:41,neodev,0.7345,27597779,CAN,AB,Calgary,68.146.86.137,FLUORIDE causes DENTAL FLUOROSIS,489,242,,497,258,causes,0.898026510133875,903790-FS1-4,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of DENTAL FLUOROSIS may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the FLUORIDE concentration in drinking water.",FLUORIDE,DENTAL FLUOROSIS,RO-has_causative_agent
502813500,7/13/2014 15:36:25,,1321943512,7/13/2014 15:36:15,neodev,0.7292,28336203,USA,PA,Harrisburg,50.149.53.150,HENOCH SCHONLEIN PURPURA causes NONTHROMBOCYTIC PURPURA,18,84,,41,108,causes,0.919145030018058,904727-FS1-4,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA,RO-has_definitional_manifestation
502813500,7/13/2014 16:11:18,,1321956740,7/13/2014 16:10:39,fusioncash,0.6208,22139728,USA,"","",66.67.91.242,no_relation,18,84,,41,108,causes,0.919145030018058,904727-FS1-4,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA,RO-has_definitional_manifestation
502813500,7/13/2014 16:13:44,,1321957790,7/13/2014 16:13:19,neodev,0.6407,14861092,GBR,I2,Manchester,90.194.137.76,HENOCH SCHONLEIN PURPURA causes NONTHROMBOCYTIC PURPURA,18,84,,41,108,causes,0.919145030018058,904727-FS1-4,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA,RO-has_definitional_manifestation
502813500,7/13/2014 16:22:14,,1321960844,7/13/2014 16:21:48,prodege,0.6149,28039757,GBR,L8,Southport,109.155.158.54,no_relation,18,84,,41,108,causes,0.919145030018058,904727-FS1-4,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA,RO-has_definitional_manifestation
502813500,7/13/2014 16:25:38,,1321962175,7/13/2014 16:25:13,prodege,0.675,19192508,USA,OK,Broken Arrow,70.177.111.89,HENOCH SCHONLEIN PURPURA causes NONTHROMBOCYTIC PURPURA,18,84,,41,108,causes,0.919145030018058,904727-FS1-4,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA,RO-has_definitional_manifestation
502813500,7/13/2014 16:31:06,,1321964726,7/13/2014 16:30:47,elite,0.304,28276268,USA,CA,San Diego,76.88.95.100,NONTHROMBOCYTIC PURPURA causes HENOCH SCHONLEIN PURPURA,18,84,,41,108,causes,0.919145030018058,904727-FS1-4,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA,RO-has_definitional_manifestation
502813500,7/13/2014 16:35:34,,1321966475,7/13/2014 16:35:21,instagc,0.4853,25990856,USA,NV,Las Vegas,68.108.98.78,no_relation,18,84,,41,108,causes,0.919145030018058,904727-FS1-4,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA,RO-has_definitional_manifestation
502813501,7/13/2014 15:34:16,,1321942633,7/13/2014 15:34:06,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,NONTHROMBOCYTIC PURPURA diagnosed by HENOCH SCHONLEIN PURPURA,18,84,,41,108,diagnosed by,0.393919298579168,904727-FS1-13,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA,RO-has_definitional_manifestation
502813501,7/13/2014 15:34:53,,1321942799,7/13/2014 15:34:23,clixsense,0.9167,15189335,GBR,K3,Peterborough,81.156.166.189,HENOCH SCHONLEIN PURPURA diagnosed by NONTHROMBOCYTIC PURPURA,18,84,,41,108,diagnosed by,0.393919298579168,904727-FS1-13,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA,RO-has_definitional_manifestation
502813501,7/13/2014 15:36:25,,1321943513,7/13/2014 15:36:15,neodev,0.7292,28336203,USA,PA,Harrisburg,50.149.53.150,HENOCH SCHONLEIN PURPURA diagnosed by NONTHROMBOCYTIC PURPURA,18,84,,41,108,diagnosed by,0.393919298579168,904727-FS1-13,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA,RO-has_definitional_manifestation
502813501,7/13/2014 15:38:57,,1321944512,7/13/2014 15:38:42,instagc,0.7153,18960682,GBR,"","",86.29.147.112,HENOCH SCHONLEIN PURPURA diagnosed by NONTHROMBOCYTIC PURPURA,18,84,,41,108,diagnosed by,0.393919298579168,904727-FS1-13,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA,RO-has_definitional_manifestation
502813501,7/13/2014 15:44:36,,1321946668,7/13/2014 15:43:56,prodege,0.6736,27096445,GBR,H9,London,86.186.168.254,HENOCH SCHONLEIN PURPURA diagnosed by NONTHROMBOCYTIC PURPURA,18,84,,41,108,diagnosed by,0.393919298579168,904727-FS1-13,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA,RO-has_definitional_manifestation
502813501,7/13/2014 15:52:39,,1321949561,7/13/2014 15:52:05,uniquerewards,0.6917,20281752,GBR,M1,Slough,86.136.105.36,HENOCH SCHONLEIN PURPURA diagnosed by NONTHROMBOCYTIC PURPURA,18,84,,41,108,diagnosed by,0.393919298579168,904727-FS1-13,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA,RO-has_definitional_manifestation
502813501,7/13/2014 15:58:44,,1321951993,7/13/2014 15:58:30,clixsense,0.6639,27793793,GBR,C5,Chester,151.230.27.155,HENOCH SCHONLEIN PURPURA diagnosed by NONTHROMBOCYTIC PURPURA,18,84,,41,108,diagnosed by,0.393919298579168,904727-FS1-13,The appearance of NONTHROMBOCYTIC PURPURA is an important clue for the diagnosis of HENOCH SCHONLEIN PURPURA (HSP.,NONTHROMBOCYTIC PURPURA,HENOCH SCHONLEIN PURPURA,RO-has_definitional_manifestation
502813502,7/13/2014 15:39:13,,1321944600,7/13/2014 15:38:59,instagc,0.7153,18960682,GBR,"","",86.29.147.112,no_relation,19,0,,58,6,causes,0.320256307610174,900197-FS1-4,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,RO-cause_of
502813502,7/13/2014 15:57:45,,1321951580,7/13/2014 15:57:32,clixsense,0.6639,27793793,GBR,C5,Chester,151.230.27.155,SEPSIS causes SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,19,0,,58,6,causes,0.320256307610174,900197-FS1-4,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,RO-cause_of
502813502,7/13/2014 16:15:14,,1321958487,7/13/2014 16:14:51,neodev,0.6407,14861092,GBR,I2,Manchester,90.194.137.76,no_relation,19,0,,58,6,causes,0.320256307610174,900197-FS1-4,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,RO-cause_of
502813502,7/13/2014 16:30:20,,1321964385,7/13/2014 16:29:51,elite,0.304,28276268,USA,CA,San Diego,76.88.95.100,SEPSIS causes SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,19,0,,58,6,causes,0.320256307610174,900197-FS1-4,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,RO-cause_of
502813502,7/13/2014 16:36:09,,1321966792,7/13/2014 16:35:56,instagc,0.4853,25990856,USA,NV,Las Vegas,68.108.98.78,no_relation,19,0,,58,6,causes,0.320256307610174,900197-FS1-4,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,RO-cause_of
502813502,7/13/2014 16:48:40,,1321971317,7/13/2014 16:48:11,neodev,0.7345,27597779,CAN,AB,Calgary,68.146.86.137,no_relation,19,0,,58,6,causes,0.320256307610174,900197-FS1-4,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,RO-cause_of
502813502,7/13/2014 17:00:25,,1321975296,7/13/2014 16:59:11,clixsense,0.5437,28037714,GBR,I4,Mitcham,94.4.232.118,no_relation,19,0,,58,6,causes,0.320256307610174,900197-FS1-4,SEPSIS refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,RO-cause_of
502813503,7/13/2014 15:33:55,,1321942518,7/13/2014 15:33:40,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,VIRUS causes MUCOUS TRANSPORT DURING VIRUS INFECTION,49,25,,54,64,causes,0.774596669241483,903829-FS1-4,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION,RO-has_causative_agent
502813503,7/13/2014 15:37:16,,1321943874,7/13/2014 15:36:49,neodev,0.7292,28336203,USA,PA,Harrisburg,50.149.53.150,VIRUS causes MUCOUS TRANSPORT DURING VIRUS INFECTION,49,25,,54,64,causes,0.774596669241483,903829-FS1-4,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION,RO-has_causative_agent
502813503,7/13/2014 15:42:37,,1321945869,7/13/2014 15:42:29,neodev,0.6488,17610000,GBR,I2,Manchester,90.200.140.201,VIRUS causes MUCOUS TRANSPORT DURING VIRUS INFECTION,49,25,,54,64,causes,0.774596669241483,903829-FS1-4,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION,RO-has_causative_agent
502813503,7/13/2014 16:12:50,,1321957457,7/13/2014 16:12:22,fusioncash,0.6208,22139728,USA,"","",66.67.91.242,no_relation,49,25,,54,64,causes,0.774596669241483,903829-FS1-4,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION,RO-has_causative_agent
502813503,7/13/2014 16:15:52,,1321958726,7/13/2014 16:15:15,neodev,0.6407,14861092,GBR,I2,Manchester,90.194.137.76,VIRUS causes MUCOUS TRANSPORT DURING VIRUS INFECTION,49,25,,54,64,causes,0.774596669241483,903829-FS1-4,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION,RO-has_causative_agent
502813503,7/13/2014 16:20:23,,1321960213,7/13/2014 16:19:33,rewardsspot,0.5812,24482174,GBR,H9,London,46.23.68.180,VIRUS causes MUCOUS TRANSPORT DURING VIRUS INFECTION,49,25,,54,64,causes,0.774596669241483,903829-FS1-4,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION,RO-has_causative_agent
502813503,7/13/2014 16:45:55,,1321970224,7/13/2014 16:45:33,instagc,0.5933,24252915,GBR,B7,Bristol,77.98.139.82,no_relation,49,25,,54,64,causes,0.774596669241483,903829-FS1-4,Disturbances in tracheal MUCOUS TRANSPORT DURING VIRUS INFECTION appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial VIRUS infection.,VIRUS,MUCOUS TRANSPORT DURING VIRUS INFECTION,RO-has_causative_agent
